Biglycan promotes tumour proliferation and invasion in human colon cancers

Biyan Lu,Ying Zhu,Guangliu Li,Yongqiang Xu,Chuangyu Wen,Weibiao Ye
DOI: https://doi.org/10.1177/03000605241300067
2024-12-01
Journal of International Medical Research
Abstract:Journal of International Medical Research, Volume 52, Issue 11, November 2024. ObjectiveTo investigate the role of biglycan (BGN) in colon cancer progression.MethodsThe association between BGN mRNA levels and the survival time of patients with colon cancer was analysed by referencing data from the Gene Expression Omnibus and The Cancer Genome Atlas (TCGA). Gene Set Enrichment Analysis (GSEA) was conducted to explore gene sets and pathways associated with BGN. In vitro analyses were undertaken in HCT116 cells to analyse cell proliferation, migration, invasion, cell cycle control and apoptosis. GSEA, Western blot analysis and small interfering RNAs were used to explore the molecular mechanisms of BGN in colon cancer cells.ResultsAnalysis of the pairs of tissues from colon cancer patients showed that BGN protein levels were higher in colon cancer tissues compared with adjacent non-tumour tissues. High BGN levels were significantly associated with shorter survival times. BGN knockdown inhibited cell proliferation, migration and invasion; and induced cell cycle arrest in the G0/G1 phase and promoted apoptosis in HCT116 cells. GSEA found that BGN might affect tumour progression via the mitogen-activated protein kinase (MAPK) signalling pathway.ConclusionBGN might promote colon cancer progression via the MAPK signalling pathway and could be a potential target for future novel therapeutic strategies.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?